Cytokinetics Inc (CYTK) stock
CYTKNasdaqPharmaceutical PreparationsFiscal year ends December 31
$51.32−0.33 (-0.64%)
Close on Nov 18, 2026Market cap $7.13BP/E –Yield –
Cytokinetics net income
Net income is the profit left for shareholders after every expense, interest and tax.
Cytokinetics's net income for the twelve months ending Jun 30, 2026 was -$894.00M. For fiscal 2025 it was -$784.96M. The highest annual figure on record is $24.54M in fiscal 2009.
Annual net income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$784.96M | – |
| FY2024 | Dec 31, 2024 | -$589.53M | – |
| FY2023 | Dec 31, 2023 | -$526.24M | – |
| FY2022 | Dec 31, 2022 | -$388.96M | – |
| FY2021 | Dec 31, 2021 | -$215.31M | – |
| FY2020 | Dec 31, 2020 | -$127.29M | – |
| FY2019 | Dec 31, 2019 | -$121.69M | – |
| FY2018 | Dec 31, 2018 | -$106.29M | – |
| FY2017 | Dec 31, 2017 | -$127.79M | -876.7% |
| FY2016 | Dec 31, 2016 | $16.45M | – |
| FY2015 | Dec 31, 2015 | -$37.50M | – |
| FY2014 | Dec 31, 2014 | -$14.65M | – |
| FY2013 | Dec 31, 2013 | -$33.72M | – |
| FY2012 | Dec 31, 2012 | -$40.37M | – |
| FY2011 | Dec 31, 2011 | -$47.86M | – |
| FY2010 | Dec 31, 2010 | -$49.29M | -300.8% |
| FY2009 | Dec 31, 2009 | $24.54M | – |
| FY2008 | Dec 31, 2008 | -$56.37M | – |
| FY2007 | Dec 31, 2007 | -$48.89M | – |
| FY2006 | Dec 31, 2006 | -$57.12M | – |
| FY2005 | Dec 31, 2005 | -$42.25M | – |
| FY2004 | Dec 31, 2004 | -$37.20M | – |
| FY2003 | Dec 31, 2003 | -$32.69M | – |
| FY2002 | Dec 31, 2002 | -$23.08M | – |
| FY2001 | Dec 31, 2001 | -$15.87M | – |
| FY2000 | Dec 31, 2000 | -$13.08M | – |
| FY1999 | Dec 31, 1999 | -$7.34M | – |
Quarterly net income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$198.76M | – |
| Q1 FY2026 | Mar 31, 2026 | -$206.03M | – |
| Q4 FY2025 | Dec 31, 2025 | -$183.03M | – |
| Q3 FY2025 | Sep 30, 2025 | -$306.18M | – |
| Q2 FY2025 | Jun 30, 2025 | -$134.37M | – |
| Q1 FY2025 | Mar 31, 2025 | -$161.38M | – |
| Q4 FY2024 | Dec 31, 2024 | -$150.02M | – |
| Q3 FY2024 | Sep 30, 2024 | -$160.55M | – |
| Q2 FY2024 | Jun 30, 2024 | -$143.32M | – |
| Q1 FY2024 | Mar 31, 2024 | -$135.64M | – |
| Q4 FY2023 | Dec 31, 2023 | -$136.90M | – |
| Q3 FY2023 | Sep 30, 2023 | -$129.42M | – |
| Q2 FY2023 | Jun 30, 2023 | -$128.64M | – |
| Q1 FY2023 | Mar 31, 2023 | -$131.29M | – |
| Q4 FY2022 | Dec 31, 2022 | -$137.38M | – |
| Q3 FY2022 | Sep 30, 2022 | -$142.31M | – |
| Q2 FY2022 | Jun 30, 2022 | -$19.82M | – |
| Q1 FY2022 | Mar 31, 2022 | -$89.45M | – |
| Q4 FY2021 | Dec 31, 2021 | -$30.57M | – |
| Q3 FY2021 | Sep 30, 2021 | -$76.09M | – |
| Q2 FY2021 | Jun 30, 2021 | -$61.55M | – |
| Q1 FY2021 | Mar 31, 2021 | -$47.10M | – |
| Q4 FY2020 | Dec 31, 2020 | -$43.93M | – |
| Q3 FY2020 | Sep 30, 2020 | -$3.18M | – |
| Q2 FY2020 | Jun 30, 2020 | -$40.78M | – |
| Q1 FY2020 | Mar 31, 2020 | -$39.41M | – |
| Q4 FY2019 | Dec 31, 2019 | -$30.64M | – |
| Q3 FY2019 | Sep 30, 2019 | -$29.57M | – |
| Q2 FY2019 | Jun 30, 2019 | -$32.11M | – |
| Q1 FY2019 | Mar 31, 2019 | -$29.37M | – |
| Q4 FY2018 | Dec 31, 2018 | -$26.47M | – |
| Q3 FY2018 | Sep 30, 2018 | -$22.02M | – |
| Q2 FY2018 | Jun 30, 2018 | -$27.52M | – |
| Q1 FY2018 | Mar 31, 2018 | -$30.28M | – |
| Q4 FY2017 | Dec 31, 2017 | -$40.48M | -665.7% |
| Q3 FY2017 | Sep 30, 2017 | -$32.36M | -197.0% |
| Q2 FY2017 | Jun 30, 2017 | -$29.08M | – |
| Q1 FY2017 | Mar 31, 2017 | -$25.87M | – |
| Q4 FY2016 | Dec 31, 2016 | $7.16M | – |
| Q3 FY2016 | Sep 30, 2016 | $33.36M | – |
See a number that looks wrong?